54
Participants
Start Date
September 13, 2018
Primary Completion Date
December 31, 2025
Study Completion Date
July 31, 2027
Ruxolitinib
"Phase I: Ruxolitinib at assigned dose\* twice daily by mouth begin Day 1 and continuing daily until study treatment stop.~* Dose Levels:~ 1. (starting) : 10mg twice daily 2: 15mg twice daily 3: 20mg: twice daily~Phase II: Ruxolitinib 20mg twice daily by mouth begin Day 1 and continuing daily until study treatment stop."
Nivolumab
Nivolumab 480 mg IV every 4 weeks (Day 1) Until disease progression, unacceptable toxicity, patient refusal or a maximum of 2 years
WITHDRAWN
Indiana Melvin and Bren Simon Comprehensive Cancer Center, Indianapolis
ACTIVE_NOT_RECRUITING
University of Iowa Hospitals and Clinics, Iowa City
RECRUITING
University of Wisconsin, Madison
RECRUITING
University of Minnesota, Minneapolis
COMPLETED
University of Illinois Cancer Center, Chicago
Collaborators (2)
Incyte Corporation
INDUSTRY
Bristol-Myers Squibb
INDUSTRY
Veronika Bachanova
OTHER